Internal

sanofi

Sanofi championing efforts in *decarbonizing the patient journey* to be showcased at COP27



Aim to deliver *net zero patient care* through healthcare stakeholder engagement and new way to deliver healthcare services:

- Sanofi sponsored study on telemedicine GHG emissions in Egypt¹
- Study on Dupixent[®] patient care pathway decarbonization
- Product environment life cycle analysis performed on different products such as Dupixent[®], Fluzone HD[®], Praluent[®], Allegra[®]
- Sanofi is driving the engagement with stakeholders such as authorities, payers, service providers, HCP and patients






is the part of patient care pathway in healthcare systems CO₂ emissions

1. In collaboration with Ain Shams University

Internal

Advancing toward

our net zero target



Delivering positive impact on communities and the environment

Mangroves

19,500 tCO2e/year carbon removed over 20 years

- ✓ Improving biodiversity
- Additional income from mangrove timber



sanof

Optimized cookstoves

52,000 tCO2e/year emissions reduction over 15 years

- ✓ Reducing disease related to smoke inhalation
- Reducing time spent collecting wood



2 Investor Relations



ESG appendices

sanofi

sanofi

Sanofi ESG Q3 achievements

Affordable access




Rare disease vials donation

Global Health Unit #Patients treated

Q2 2022	Q3 2022	Q2 2022	Q3 2022			
Malaria 1,693,770 10 countries	Malaria 2,000,995 13 countries	1,015 patients treated	1,064 patients treated			
10 countries		51,370 vials donated	76,494 vials donated			
Tuberculosis 76,634 13 countries	Tuberculosis 98,542 13 countries	Global access plan				
13 countries	13 countries	Global access	pian			
13 countries	13 countries	Q2 2022	Q3 2022			

R&D for unmet needs



Polio eradication

Q2 2022	Q3 2022				
27 million IPV doses supplied to UNICEF	38 million IPV doses supplied to UNICEF				
Sleeping sickness elimination					
Sleeping sickn	ess elimination				
FY 2021 ¹ 2 million	ess elimination FY 2022				

805

patients treated

Pediatric cancer treatment development

	Q2 2022	Q3 2022 😑
	1 asset in pre-clinical assessments	1 asset in pre-clinical assessments
n	1 asset in protocol preparation for clinical study	1 asset in protocol preparation for clinical study

Data in YTD unless stated otherwise. 1. Data provided by WHO.

sanofi

Sanofi ESG Q3 achievements



Scope 1 & 2

Blister-free syringe vaccines

In and beyond the workplace



Diverse Senior Leadership

Engagement with communities

Rollout planned

in 2022

Program

launched

Q2 2022	Q3 2022	Q2 2022	Q3 2022		
35.9% of our executives and 41.1% of	36.2% of our executives and 41.4% of our senior leaders were	1,998 volunteers	3,498 volunteers		
our senior leaders were		12,687 hours	25,265 hours		
women	women	From Leaders to Citizens			
		Q2 2022	Q3 2022		

Data in YTD unless stated otherwise.

sanofi

Sanofi ESG ratings

Rating agencies

<mark>S&P Global</mark> Ratings	SUSTAINALYTICS	Dow Jones Sustainability Indexes	MSCI 🛞	CDP	ISS-oekom►	FTSE4Good	access to medicine Index	B WD: Voldee Dacent Hiller	vigeœiris
SCORE									
86/100	21.6 Medium risk	69/100	A	Climate Change: A Water: A	в	4.3/5	3.47/5	92%	64/100
New rating	2 2	74/100	= A	🔺 A-	= в	4.2/5	a 2.49/5	A 90%	▲ 62/100
One of the highest scores across all sectors globally 80 points for its solid fundamentals & strong preparedness opinion of 6 points	12 th among 455 pharmaceutical companies	Percentile of 92 within 143 scored companies in the industry	Within the top 6 highest rated pharmaceutical companies	Leading position	1 st decile of the 476 companies in the industry	With very high rating across the 3 pillars ESG	Top 5 company	Sanofi's disclosure score well above sector disclosure score (74%)	1 st pharmaceutical company out of 57 Score in progress since 2018



Scores assigned by the rating agencies are not equivalent.